Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33797023/

doi: 10.1007/s12282-021-01239-8. Online ahead of print. 1 Saitama Cancer Center, Saitama, Japan. 2 National Hospital Organization, Osaka National Hospital, Osaka, Japan. 3 Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. 4 National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan. 5 The Cancer Institute Hospital, Tokyo, Japan.